相关实验视频
Updated: Jul 7, 2025

09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
6.6K
具有增强抗癌活性的双重向化合物,通过微管破坏和素脱乙酶抑制增强抗癌活性
Yu-Wei Tseng1, Tsung-Jung Yang1, Yuan-Ling Hsu2
1Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan.
European journal of medicinal chemistry
|December 23, 2023
概括
新的双重向抗癌药物结合了微管破坏和HDAC抑制. 这些纯氨酸-胺酸结合物对各种癌细胞具有强烈的细胞毒性,并且在没有毒性的小鼠中减少瘤生长.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 开发针对多种途径的新型抗癌剂对于克服耐药性至关重要.
- 基因组脱乙酶 (HDAC) 和微管是癌症治疗中验证的标.
- 结合微管破坏剂和HDAC抑制剂的结构特征,为双重向治疗提供了一个有希望的策略.
研究的目的:
- 设计和合成新的双重向抗癌药物,通过将基于纯素的微管抑制剂与HDAC抑制剂结合在一起.
- 评估合成化合物的HDAC抑制活性,微管破坏作用和细胞毒性.
- 在临床前癌症模型中评估化合物的体内疗效和安全性.
主要方法:
- 合成一个库的氨酸-酸盐结合化合物与不同的链接剂和替代剂.
- 在体外测试以确定HDAC抑制活性,包括I类HDAC.
- 通过测量卡塔宁激活来评估微管片段的碎片化.
- 与具有不同EGFR状态的人类癌细胞系 (例如MDA-MB231,H1975) 组的细胞毒性评估.
- 在小鼠体内研究以评估瘤生长抑制和毒性.
主要成果:
- 合成的 purin-hydroxamate 合物表现出显著的 HDAC 抑制活性,特别是在对抗 I 类 HDAC 的情况下.
- 化合物通过卡塔宁激活诱导微管碎片化.
- 对乳腺和肺癌细胞系,包括临床隔离物,观察到增强的细胞毒性.
- 基替代剂提高了溶解性和增加了细胞毒性.
- 在体内给药导致小鼠显著减少瘤生长,没有明显的毒性影响.
结论:
- 开发的精氨酸-胺酸合物代表了一种新型的双重向抗癌剂.
- 这些化合物有效地抑制HDACs并破坏微管,从而产生强大的抗癌活性.
- 有希望的临床前疗效和安全性概况表明它们有可能用于癌症单一治疗.
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

